Merck's Story: How an '$11 Billion by 2030' Promise Quietly Disappeared

The story

Late 2023: "nothing has changed"

On the Q3 FY2023 call, Merck management said flatly, "our expectation to deliver over $11 billion by 2030 remains unchanged... nothing has changed," referring to its cervical-cancer vaccine, Gardasil. On the Q4 FY2023 call (February 2024), Gardasil sales had grown 27%, described as "exceptional growth." That era's 10-K stated that Merck's China business "has grown rapidly in the past few years."

Mid-2024: cracks appear, confidence doesn't

Merck's Chinese distribution partner, Zhifei, began building up excess Gardasil inventory, and Q3 FY2024 Gardasil sales fell 10% year over year — the first decline ever. Even so, on the Q2 FY2024 call, management repeated more than five times that it remained confident in the "$11 billion by 2030" target "even accounting for what's happening in China." Confidence held publicly even as conditions on the ground weren't matching it.

Q4 FY2024: the target is formally withdrawn

On the Q4 FY2024 call (February 2025), management said it judged it "prudent" to withdraw the target, citing uncertainty about the timing of China's economic recovery — ending nearly three years of repeated reaffirmation. On that same call, when an analyst asked when the company might issue new long-term guidance ahead of the looming Keytruda patent cliff, CEO Robert Davis said the company "hadn't yet decided" whether to issue long-term guidance at all — the withdrawal of one product's target rippled into how the entire company talked about its future. First-half 2025 Gardasil sales fell as much as 55% year over year, the low point of the decline.

Now: the first green shoot

On the Q2 FY2026 call — marking Robert Davis's fifth anniversary as CEO — he said the company was "much stronger and more diversified" than five years earlier, and that same quarter, Gardasil sales turned positive (+3%) for the first time in about two years. Instead of a specific long-term number tied to one product, the company now talks about "more than $70 billion in commercial opportunity from 20-plus new products" — a broader, harder-to-verify framing than the number it retired.

Guidance scorecard

Two different tracks with two very different records: company-wide annual revenue guidance kept a conservative "raise and narrow" practice for three straight years and hit it every time — even in 2025, when Gardasil collapsed, because other products picked up the slack. A single product's long-term (2030) target, by contrast, was reaffirmed with "nothing has changed" for nearly three years, then withdrawn entirely in one quarter. Short-term, company-wide guidance here has a reliable track record; long-term, single-product promises deserve more skepticism.

Source: Q4 FY2023, Q4 FY2024, Q4 FY2025, and Q2 FY2026 earnings calls; Q3 FY2023 through Q3 FY2024 calls (2030 target reaffirmations).

Timeline

• Oct 2023Q3 2023 call: "nothing has changed" on the 2030 $11B+ Gardasil target.
• Q3 2024Gardasil sales fall 10% YoY, the first-ever decline, tied to Chinese distributor Zhifei's inventory buildup.
• Feb 2025Q4 2024 call: the 2030 Gardasil target is formally withdrawn; CEO says the company hasn't decided on future long-term guidance.
• Mid-2025Gardasil sales fall as much as 55% YoY; new tariff costs ($200M) recognized.
• Late 2025Q4 2025 call: an analyst is first to note the company held full-year guidance despite Gardasil pressure — a turning point.
• Aug 2026Q2 2026 call: Gardasil sales turn positive (+3%) for the first time in about two years; CEO marks his 5-year anniversary reflecting on the company's progress.

Our read

Merck's last three years show a company that held firm on a specific, dated long-term promise well past the point where the underlying data supported it, then withdrew that promise entirely in a single quarter once the gap became undeniable. What's reassuring is that company-wide, short-term guidance stayed reliable throughout, even during Gardasil's worst stretch — other products absorbed the shock. What's worth remembering is that the company has since moved toward broader, less specific language about future opportunity, which is harder for outsiders to hold it accountable to the next time results disappoint.

What we still don't know

• Whether Q2 FY2026's Gardasil +3% is a genuine trend reversal or simply reflects a weak 2025 comparison base requires another quarter or two to confirm.
• What specific products and timeline underlie the new "$70 billion-plus commercial opportunity" framing isn't broken down in the filings reviewed here — investor-conference materials would need to be checked.
• Whether inventory normalization with Chinese distributor Zhifei is fully complete, or some regional overstock remains isn't fully confirmed by the earnings calls reviewed alone.